Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1517 - Diabetes Is Associated With Pancreatic Neuroendocrine Tumors Growth and Metastasis

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Zhiyao Fan

Citation

Annals of Oncology (2019) 30 (suppl_5): v564-v573. 10.1093/annonc/mdz256

Authors

Z. Fan1, G. Luo2, C. Liu2, X. Yu1

Author affiliations

  • 1 Department Of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 2 Pancreatic Surgery, shanghai cancer center, 200030 - Shanghai/CN
More

Resources

Abstract 1517

Background

Previous studies have demonstrated an association between type 2 diabetes mellitus (T2DM) and several types of cancers. However, the role of T2DM in pancreatic neuroendocrine tumors (pNETs) has not been systemically studied.

Methods

A retrospective, follow-up cohort analysis including 299 patients with pNETs was performed. The clinicopathologic characteristics between diabetics and nondiabetic were compared. The overall survival (OS) and progression-free survival (PFS) separated by diabetics and nondiabetic status were analyzed. The association between metformin use and survival was assessed to confirm whether metformin has an impact on prognosis of pNETs.

Results

The prevalence of T2DM was 20.7% (n = 62) in the cohort. For both OS and PFS, diabetic status was associated with a dismal outcome in univariate analyses, and the association was not exist when controlled by stage. The proportion of grade 3 tumor, distant metastasis and nerve invasion was higher in pNETs patients with T2DM than that of patients without T2DM. According to the result of logit regression, pNETs patients with T2DM were at high risk of tumor metastasis (OR = 2.81, P = 0.001), nerve invasion (OR = 2.43, P = 0.029) and grade 3 tumor (OR = 4.97, P = 0.010). Multivariate analysis demonstrated that T2DM was not an independent predictor of OS (P = 0.742) and PFS (P = 0.917). In subset analysis, no significant differences were observed for OS and PFS in subgroup according to their metformin usage.

Conclusions

T2DM is associated with pNETs growth and metastasis, and is not an independent risk factor of poor prognosis in patients with pNETs. No significant association is found between metformin use and survival in pNETs patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Xianjun Yu.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.